In Conversation

"Our engagement with industry is equally proactive, collaborative, and transparent."

"The company invests a lot into education with doctors, using them as a middle man between the company and the patients."

"In Canada, we look to industry to partner with us on research activities. In addition, we also try to assist in building the right conditions (a…

"When looking at pharmaceuticals and the health sector, Serbia suffers from similar problems to the rest of Eastern Europe."

"It bears mentioning that Lithuania has good level of inclusion of new chemical entities into the reimbursement list and, indeed, around 50 new products have been…

"First, our overarching objective is to increase the number of Brazilian patients annually treated with AstraZeneca products from around 3.2 million today to over five million…

"As the premier research based company in the world, we are strongly committed to remain at the forefront of the Polish innovative landscape."

"We are not only interested in global or territorial rights to products that we can in-license or acquire, but want to secure manufacturing rights for those…

"I personally believe that the first and foremost mission of any general manager is to build and enhance enriching work relationships – both at the internal…

"Rare diseases affect – in total - a large population. However, individual rare diseases are very heterogeneous and people affected by these as well as their…

Looking at our productivity in 2017 alone, which includes three new therapy approvals, it is clear that the model we established makes good sense

"Serbia really has a huge potential especially in the innovation and technology sectors, but current developments in these areas are still modest."

We use cookies to ensure that we give you the best experience on our site. For more info

See our Cookie Privacy Policy Here